fbpx Yourgene Health plc - Home
DSC00185r.jpg
003-news.jpg
004-news.jpg
001-news.jpg
002-news.jpg
previous arrow
next arrow

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Contract manufacturing agreement for COVID-19 diagnostic test

Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an agreement for contract manufacturing services with Novacyt S.A. (“Novacyt”, EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division.

Yourgene will make use of its state-of-the-art manufacturing facility at Citylabs in Manchester, UK, to work alongside Novacyt to ramp-up production of their COVID-19 test. The first batches are expected to be shipped from the Citylabs site over the next few weeks. In the interest of speed, the Company will initially manufacture critical components for Primerdesign’s COVID-19 test. The two companies may subsequently seek to expand the agreement to utilize Yourgene’s ability to produce final versions of the COVID-19 testing kits.

Yourgene’s GMP (Good Manufacturing Practices) facility has the capacity to support the manufacture of critical components for the production of COVID-19 diagnostic tests, whilst continuing its own PCR (polymerase chain reaction) production. Should the requirement to produce COVID-19 tests expand, the Company may need to increase capacity to replenish PCR stocks and maintain continuity of supply of existing Yourgene product lines. The Company is well prepared to do this and is able to utilise its expertise in automation to assist in the scale up of production.

In addition to supporting manufacturing efforts, the Company is also in the process of expanding its laboratory capabilities to support the NHS in COVID-19 laboratory service testing. This is developing quickly, and the Company will update the market as and when these capabilities are in place and set to be utilised.

Expanding into another diagnostic test aligns with Yourgene’s strategy to expand the Company’s product portfolio and bring new products to market.

Lyn Rees, CEO of Yourgene, commented: “We are pleased to be able to utilise our high quality manufacturing skills to support Novacyt in the production of a key diagnostic test for COVID-19. This manufacturing agreement illustrates that we have an incredibly skilled workforce and flexible manufacturing capabilities to support diagnostic test developers at critical times.

“Business demand for our core products and services is proving to be very resilient to current market conditions, albeit with isolated areas of friction for travel or customs restrictions. I would like to thank our committed workforce for their tremendous endeavours in supporting the medical supply chain at this time.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (NOMAD)

Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

Stifel Nicolaus Europe Limited (Sole Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.



  • 28 September 2021 - AGM Statement Investor presentation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement
    Investor presentation

    Manchester , UK - 28 September 2021 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM) at 4:00pm today.  In-person registration for this meeting is now closed due to COVID-19 protocols in place but investors can still attend via the Investor Meet Company website as described at the end of this notice.

    At the meeting Adam Reynolds, Non-executive

    Read More
  • 10 September 2021 - Further re: DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further re: DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the Department of Health & Social Care (“DHSC”) for the provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing, as announced

    Read More
  • 1 September 2021 - Yourgene Genomic Services receive ISO 15189:2012 accreditation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services receive ISO 15189:2012 accreditation
    Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality levels of performance and competence

    Manchester, UK – 1 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following assessments by the UK accreditation service (UKAS), it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services,

    Read More
  • 1 September 2021 - Notice of AGM and Annual Report 2021 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Notice of AGM and Annual Report 2021
    Investor presentation

    Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy will shortly be available on the Company’s website at: www.yourgene-health.com/investors/key-documents/shareholder-communications  and are being posted to those shareholders who have opted out of electronic communications.

    The Annual Report and Accounts

    Read More
  • 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s COVID-19 testing investment reaps rewards
    DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services (‘YGS’) has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

    In April

    Read More
  • 11 August 2021 - Earn-out Milestone, Issue of Equity & Total Voting Rights +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Earn-out Milestone, Issue of Equity & Total Voting Rights

    Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity pursuant to the terms of the acquisition of Coastal ® Genomics Inc. ("Coastal") which completed in August 2020 (the “Acquisition”).

    Under the terms of the Coastal acquisition, a second strategic partnership Coastal Genomics’ Ranger ® technology was announced on

    Read More
  • 11 August 2021 - Audited Final results and unaudited Q1 business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Audited Final results and unaudited Q1 business update

    Manchester, UK – 11 August 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its full year financial results for the year ended 31 March 2021 (“FY21”), and provides a business update after its first trading quarter of the current financial year (Q1).

    The FY21 results, delivered in-line with prior guidance, reflect resilient revenue growth through the

    Read More
  • 21 June 2021 - Second Strategic Partner for Coastal Genomics +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Second Strategic Partner for Coastal Genomics

    Manchester, UK – 21 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s wholly-owned US subsidiary, has signed a Master Supply Agreement (“MSA”) (the “Agreement”) with a leading US laboratory services provider (“the Partner”). The Agreement provides the Partner with non-exclusive use of the Group’s Ranger TM Technology, which was acquired with

    Read More
  • 18 June 2021 - Contract Award for the supply of DPYD testing kits to NHS Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract Award for the supply of DPYD testing kits to NHS Wales
    Estimated to be worth £232,000 across two years

     

    Manchester, UK –  June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has been awarded the contract to supply its Elucigene DPYD testing kits to NHS Wales. The contract award is for two years (for a period of 12 months with

    Read More
  • 9 June 2021 - Multi-year licence and supply agreement with leading US precision medicine company +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Multi-year licence and supply agreement with leading US precision medicine company

    Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has entered into a licence and supply agreement (the “Agreement”) with a leading US precision medicine company (the “Partner”) for an initial term of three years commencing  1 April 2022. The Agreement grants the Partner a non-exclusive licence to

    Read More
  • 19 May 2021 - Distribution Partnership for the Middle East and Africa +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Distribution Partnership for the Middle East and Africa
    Yourgene and Alliance Global launch partnership across multiple territories

    Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC (‘AGBL’ or ‘Alliance Global’) across a broad range of territories in the Middle East and Africa to expand the Company’s geographical

    Read More
  • 18 May 2021 - Launch of IONA® Care NIPT service offering +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of IONA ® Care NIPT service offering
    Extended clinical menu to screen SCAs and AAs for pregnant women

    Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Care, a non-invasive prenatal test (NIPT) service offering, with an extended clinical menu measuring the likelihood that a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA

    Read More
  • 17 May 2021 - Further testing service agreement for MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testing
    for international arrivals to the UK 

    Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) (“MyHealthChecked”) has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory

    Read More
  • 29 April 2021 - Full year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year Trading update
    10% year-on-year revenue growth

    Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the financial year ended 31 March 2021 (“FY 2021”).

    Yourgene reports unaudited revenues for FY 2021 of £18.3m (FY 2020: £16.6m), up 10% compared to the previous year.  This is in line with recently issued guidance and reflects

    Read More
  • 26 April 2021 - Further National Microbiology Framework contract awards +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further National Microbiology Framework contract awards

    Successful tenders under Lots 2 & 3 valued at a total of £4bn
    Yourgene one of only three companies to have been successfully awarded under all four lots

    Manchester, UK – 26 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tenders under PHE’s

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen